It was reported that DDR alterations are associated with higher ORR, longer PFS and OS in urothelial carcinoma and NSCLC patients treated with PD-1/PD-L1 blockade (170, 171). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.